company background image
ALKS

Alkermes NasdaqGS:ALKS Stock Report

Last Price

US$25.20

Market Cap

US$4.1b

7D

3.8%

1Y

14.0%

Updated

01 Dec, 2022

Data

Company Financials +
ALKS fundamental analysis
Snowflake Score
Valuation6/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ALKS Stock Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally.

Alkermes plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alkermes
Historical stock prices
Current Share PriceUS$25.20
52 Week HighUS$32.79
52 Week LowUS$21.34
Beta0.60
1 Month Change8.39%
3 Month Change2.82%
1 Year Change13.98%
3 Year Change22.03%
5 Year Change-52.25%
Change since IPO358.18%

Recent News & Updates

Recent updates

Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Aug 29
Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?

Jun 27
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?

Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

May 16
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Feb 07
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Alkermes plc's (NASDAQ:ALKS) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 12
Alkermes plc's (NASDAQ:ALKS) Intrinsic Value Is Potentially 100% Above Its Share Price

Is Alkermes (NASDAQ:ALKS) Weighed On By Its Debt Load?

Oct 24
Is Alkermes (NASDAQ:ALKS) Weighed On By Its Debt Load?

Is Alkermes (NASDAQ:ALKS) Weighed On By Its Debt Load?

Jul 13
Is Alkermes (NASDAQ:ALKS) Weighed On By Its Debt Load?

Shareholders May Be A Bit More Conservative With Alkermes plc's (NASDAQ:ALKS) CEO Compensation For Now

Jun 08
Shareholders May Be A Bit More Conservative With Alkermes plc's (NASDAQ:ALKS) CEO Compensation For Now

Alkermes plc (NASDAQ:ALKS): When Will It Breakeven?

Apr 08
Alkermes plc (NASDAQ:ALKS): When Will It Breakeven?

Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Mar 13
Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Alkermes (NASDAQ:ALKS) Share Prices Have Dropped 70% In The Last Three Years

Feb 15
Alkermes (NASDAQ:ALKS) Share Prices Have Dropped 70% In The Last Three Years

A Look At The Intrinsic Value Of Alkermes plc (NASDAQ:ALKS)

Jan 25
A Look At The Intrinsic Value Of Alkermes plc (NASDAQ:ALKS)

When Will Alkermes plc (NASDAQ:ALKS) Breakeven?

Jan 04
When Will Alkermes plc (NASDAQ:ALKS) Breakeven?

Have Insiders Been Buying Alkermes plc (NASDAQ:ALKS) Shares This Year?

Dec 14
Have Insiders Been Buying Alkermes plc (NASDAQ:ALKS) Shares This Year?

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Nov 27
Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Shareholder Returns

ALKSUS BiotechsUS Market
7D3.8%2.7%1.4%
1Y14.0%-10.3%-16.1%

Return vs Industry: ALKS exceeded the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: ALKS exceeded the US Market which returned -14.8% over the past year.

Price Volatility

Is ALKS's price volatile compared to industry and market?
ALKS volatility
ALKS Average Weekly Movement4.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: ALKS is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: ALKS's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19872,211Richard Popshttps://www.alkermes.com

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells.

Alkermes plc Fundamentals Summary

How do Alkermes's earnings and revenue compare to its market cap?
ALKS fundamental statistics
Market CapUS$4.14b
Earnings (TTM)-US$129.14m
Revenue (TTM)US$1.13b

3.7x

P/S Ratio

-32.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALKS income statement (TTM)
RevenueUS$1.13b
Cost of RevenueUS$217.83m
Gross ProfitUS$913.76m
Other ExpensesUS$1.04b
Earnings-US$129.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.79
Gross Margin80.75%
Net Profit Margin-11.41%
Debt/Equity Ratio28.2%

How did ALKS perform over the long term?

See historical performance and comparison